NoctuRNA Therapeutics

NoctuRNA develops first-in-class non-coding circular RNA therapeutics to treat currently incurable genetic diseases. Our lead program focuses on ALS, targeting disease-driving RNA structures. In parallel, we have demonstrated in vitro activity across additional neurodegenerative targets, including FTD and Huntington’s disease, and in vivo efficacy in myotonic dystrophy type 1. Our proprietary, patented AI-based platform enables rapid design and scalable production of circRNAs. Beyond genetic diseases, the platform has demonstrated antiviral activity (SARS-CoV-2, Dengue, West Nile Virus), highlighting its dual-use potential to rapidly respond to emerging biological threats.